Europe
Secarna Pharmaceuticals, a new breed of biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide therapies to address challenging or previously undruggable targets, announced that the Company has completed a financing round, which was open only to existing investors.
In Phase 2b development for the treatment of life-threatening fungal infections
evitria AG, a global antibody expression service provider, announces the opening of its new head office in Denmark to better serve the growing demand from Scandinavian enterprises.
Expedeon AG announces the signing of an agreement with Abcam plc, Cambridge, UK, to sell its proteomics and immunology business activities for a cash payment of EUR 120 million.
ACR Annual Meeting: Janssen’s Tremfya Nails Primary Endpoints in 24-Week Psoriatic Arthritis Studies
Both DISCOVER 1 and DISCOVER 2 are evaluating Tremfya in adults with active psoriatic arthritis.
Brown University and Hebrew SeniorLife leading research incubator
A clinical Phase II safety and efficacy trial is planned for 2020 for the treatment of influenza, an indication with a very high unmet medical need
UK Innovation & Science Seed Fund is delighted to announce it is has been awarded ‘Best Sector Support Organisation’ at the 11th Annual OBN Awards celebration last night.
Asunercept Plus Radiotherapy Significantly Prolongs Time to Deterioration of Quality of Life Compared to Radiotherapy Alone in Patients with Recurrent Glioblastoma
Genedata Selector® deployed to streamline complex cell line development processes
PRESS RELEASES